RP-6306

DRUG3 trials

Sponsors

Canadian Cancer Trials Group, University Health Network, Toronto

Conditions

Advanced CancerBreast CancerMetastatic CancerRecurrent Ovarian CancerRecurrent Uterine Cancer

Phase 1

Phase 1 Study of RP-6306 With Carboplatin and Paclitaxel in TP53 Ovarian and Uterine Cancer

Active, not recruitingNCT06107868

University Health Network, TorontoAdvanced Cancer, Metastatic Cancer, Recurrent Ovarian Cancer +1

Start: 2024-03-20End: 2026-01-30Updated: 2025-12-08

Phase 2

Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

RecruitingNCT05601440

Canadian Cancer Trials GroupBreast Cancer

Start: 2023-06-13End: 2028-06-30Target: 484Updated: 2026-03-27

RP-6306 in Patients With Advanced Cancer

CompletedNCT05605509

Canadian Cancer Trials GroupAdvanced Cancer

Start: 2023-05-24End: 2026-02-05Updated: 2026-02-06

Related Papers

IND.241: A Canadian Cancer Trials Group liquid-biopsy informed platform trial to evaluate treatment in CDK4/6-inhibitor resistant ER+/HER2- metastatic breast.

Journal of Clinical Oncology2025-05-281 citations